Advertisement
The Body: The Complete HIV/AIDS Resource Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol

10 HIV/AIDS Stories That Defined 2013 in the U.S.

December 1, 2013

 11/11 

Advances in Treatment

Advances in Treatment

The last year has seen a number of advances in treatment and medications. Stribild, a once-daily, single-pill regimen, and Tivicay, a newly approved integrase inhibitor, are now on the list of "preferred" HIV medications in the official U.S. HIV treatment guidelines -- a recommendation that was announced on Oct. 30. Until that date, only four medications were recommended for first-line treatment: Atripla, Norvir/Reyataz/Truvada, Norvir/Prezista/Truvada and Isentress/Truvada. The changes highlight "the rise of integrase inhibitors as an established, reliable family" of medications for first-line treatment, in the words of TheBody.com's Myles Helfand in a recent piece.

The price of these new medications continues to fuel a huge controversy. Tivicay is priced at more than $14,000 per year. Stribild's annual price tag approaches almost $30,000.

Also making news: On Dec. 31, 2012, the Food and Drug Administration approved Fulyzaq (crofelemer) as the first drug to relieve symptoms of diarrhea that is a side effect of HIV antiretrovirals. Current HIV medications are "aren't nearly as likely to cause diarrhea as the first generation of meds did -- but it remains a problem for many.




Rod McCullom has written and produced for ABC News, NBC and FOX, The Atlantic, the Los Angeles Times, EBONY, POZ and many others. Read his blog at Rod 2.0.


Copyright © 2013 Remedy Health Media, LLC, Inc. All rights reserved.


Related Stories

2013 Year in Review: Features and News

This article was provided by TheBody.com.
 

 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Advertisement